Evaluation of NK1 antagonists for emesis prevention in oxaliplatin chemo: SENRI trial

(European Society for Medical Oncology) The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, results of a Japanese study presented today at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona reveal.

Source: EurekAlert! - Medicine and Health - July 1, 2015 Category: Global & Universal Source Type: news